Literature DB >> 31339110

Bone mineral density loss in cirrhotics: Impact of country specific data.

Ibrahim Muhsen1, Abdullah AlKhenizan2, Fahad Alsohaibani3.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31339110      PMCID: PMC6714472          DOI: 10.4103/sjg.SJG_182_19

Source DB:  PubMed          Journal:  Saudi J Gastroenterol        ISSN: 1319-3767            Impact factor:   2.485


× No keyword cloud information.
Sir, We would like to thank the author for his comments and interest in our study.[1] Our study was the first study to be conducted in cirrhotic patients in Saudi Arabia, supporting the need to apply preventative measures for the early diagnosis and management of osteoporosis among patients with cirrhosis. Clearly, as highlighted in our study, there is a need for larger prospective cohort studies to confirm this relationship.[2] With regards to the bone mineral density reference value, this study used dual-energy X-ray absorptiometry scan (Lunar iDXA, General Electric) which is standardized based on established international reference values. Finally, the study of Ardawi et al. was relatively a small study and included individuals from one city in the country, which limited its generalizability.[3]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  3 in total

1.  Bone mineral density of the spine and femur in healthy Saudis.

Authors:  M Salleh M Ardawi; Abdulraouf A Maimany; Talal M Bahksh; Hasan A N Nasrat; Waleed A Milaat; Raja M Al-Raddadi
Journal:  Osteoporos Int       Date:  2004-05-27       Impact factor: 4.507

2.  Bone mineral density loss in patients with cirrhosis.

Authors:  Ibrahim N Muhsen; Omar AlFreihi; Faisal Abaalkhail; Abdullah AlKhenizan; Mohammed Khan; Abdelmoneim Eldali; Fahad Alsohaibani
Journal:  Saudi J Gastroenterol       Date:  2018 Nov-Dec       Impact factor: 2.485

3.  Bone mineral density loss in patients with cirrhosis.

Authors:  Mahmood Dhahir Al-Mendalawi
Journal:  Saudi J Gastroenterol       Date:  2019 May-Jun       Impact factor: 2.485

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.